Unii-4bmh7izt98
- CAS No.
- 856676-23-8
- Chemical Name:
- Unii-4bmh7izt98
- Synonyms
- Choline Fenofibrate;Trilipix;Abt 335;Unii-4bmh7izt98;Fenofibrate de choline;Unii-4bmh7izt98 USP/EP/BP;Unii-4bmh7izt98 856676-23-8;Fenofibric acid choline salt;Choline Fenofibrate (CFRC-3);Choline fenofibrate (ABT-335)
- CBNumber:
- CB62494614
- Molecular Formula:
- C22H28ClNO5
- Molecular Weight:
- 421.91442
- MOL File:
- 856676-23-8.mol
- MSDS File:
- SDS
- Modify Date:
- 2023/5/18 11:31:04
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H332-H335 |
| Precautionary statements | P261-P280-P305+P351+P338 |
| HS Code | 2923100000 |
Unii-4bmh7izt98 Chemical Properties,Uses,Production
Description
Choline fenofibrate, a salt formulation of fenofibric acid, is a lipid
regulating agent available as delayed release capsules for oral administration. It is indicated in combination with a statin to reduce TG and
increase high-density lipoprotein cholesterol (HDL-C) in patients with
mixed dyslipidemia and coronary heart disease (CHD) or a CHD-risk
equivalent who are optimal for statin therapy to achieve their lowdensity lipoprotein cholesterol (LDL-C) goal. In addition, choline
fenofibrate is indicated as monotherapy in patients with severe
hypertriglyceridemia to reduce TG, and in patients with primary
hyperlipidemia or mixed dyslipidemia to reduce elevated LDL-C, total
cholesterol, TG, apolipoprotein B, and to increase HDL-C. Fenofibric acid
is also the active metabolite of fenofibrate (Tricor), which has been
previously marketed for the treatment of hypercholesterolemia and
hypertriglyceridemia.
The primary mode of action of fenofibric acid
is through the activation of the nuclear transcription factor PPARa,
predominantly expressed in tissues that metabolize fatty acids, such as
the liver, kidney, heart, and muscle.
On activation by binding of the fibrate, PPARa binds as heterodimers with retinoid X receptor (RXR), which subsequently recognizes and binds to specific PPARa-response elements leading to modulation of expression of the target genes. In particular, the activity of lipoprotein lipase is increased and synthesis of apoprotein C-III is decreased, which together enhance the clearance of circulating TG-rich lipoproteins. The resulting fall in TG produces an alteration in the size and composition of LDL from small dense particles to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Choline fenofibriate acid is contraindicated in patients with severe renal impairment.
Chemical Properties
White Solid
Side effects
The most common adverse reactions observed with the use of fenofibric acid alone or in combination with a statin are headache, back pain, nasopharyngitis, nausea, myalgia, diarrhea, and upper respiratory tract infection.
Unii-4bmh7izt98 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Lupin Ltd | +91-8019896181 +91-8019896181 | Maharashtra, India | 93 | 58 | Inquiry |
| Alembic Pharmaceuticals Limited | +91-2652280880 +91-2652280550 | Gujarat, India | 115 | 58 | Inquiry |
| Om Pharmaceutical Industries | +91-2502344639 +91-9822376539 | Maharashtra, India | 32 | 58 | Inquiry |
| Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
| Ami Lifesciences Pvt Ltd | +91-9426998100 +91-9426998100 | Gujarat, India | 62 | 58 | Inquiry |
| Omshri Labs Pvt Ltd | +91-7977270534 +91-9833689647 | Maharashtra, India | 46 | 58 | Inquiry |
| Harman Finochem Ltd | +91-2226528080 +91-2226528080 | Maharashtra, India | 37 | 58 | Inquiry |
| HARMAN FINOCHEM LTD | +91 22 26528080 | New Delhi, India | 29 | 58 | Inquiry |
| GLENMARK LIFE SCIENCES LTD | +91 22 4018 9999 | New Delhi, India | 103 | 58 | Inquiry |
| LUPIN LTD | +91 124 4885000 / +91 124 3325000 | New Delhi, India | 191 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| Lupin Ltd | 58 |
| Alembic Pharmaceuticals Limited | 58 |
| Om Pharmaceutical Industries | 58 |
| Ralington Pharma | 58 |
| Ami Lifesciences Pvt Ltd | 58 |
| Omshri Labs Pvt Ltd | 58 |
| Harman Finochem Ltd | 58 |
| HARMAN FINOCHEM LTD | 58 |
| GLENMARK LIFE SCIENCES LTD | 58 |
| LUPIN LTD | 58 |